Doximity Disappoints with Mixed Q4, Weak Q1 Outlook; Analysts Cut Forecasts

What happened

Doximity reported mixed fiscal fourth-quarter results and issued weak first-quarter sales guidance, triggering analyst downgrades and forecast reductions. The company's performance fell short of expectations, particularly in revenue growth, raising concerns about near-term momentum. Management's weak Q1 outlook suggests headwinds from pharma budget sensitivity or competitive pressures may be intensifying. This contrasts with the prior narrative of sustained double-digit growth and margin expansion embedded in the company's FY2026 guidance. The stock faces renewed skepticism as the market reassesses the durability of Doximity's high-margin subscription model.

Implication

If the weakness is temporary and the company can reaccelerate in H2, the current pullback may present an entry point given the strong balance sheet and long-term network effects. However, sustained softness would challenge the thesis, requiring proof that Doximity can maintain its NRR and large-customer growth.

Thesis delta

The POSSIBLE BUY thesis is now under greater risk as the mixed Q4 and weak Q1 guidance contradict the expectation of steady reacceleration. The near-term catalyst path has narrowed, with execution risk elevated; a downgrade to WAIT is warranted pending evidence that growth can rebound. Key watch items shift from margin expansion to top-line resilience, with the Q4/Q1 results as a potential invalidation trigger if weakness persists.